☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
neurocrine
Neurocrine Presents P-III Studies (KINECT 3 & 4) Results of Ingrezza (valbenazine) for Tardive Dyskinesia and Schizophrenia or Sch...
May 17, 2023
Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases
January 10, 2023
Disease of the Month: Cerebral Palsy
October 18, 2022
Neurocrine Reports Results of Valbenazine in P-III (KINECT-HD) Study for the Treatment of Chorea Associated with Huntington Diseas...
December 8, 2021
PharmaShots Interview: Neurocrine's Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)
November 16, 2020
PharmaShots Weekly Snapshot (Jun 15-19, 2020)
June 22, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.